Financial Statements
for the 3rd quarter of fiscal year ending March 31, 2019
(From Apr. 1, 2018 to Dec. 31, 2018)

Summary of consolidated results

JMS Co., Ltd.
Company Code No. 7702

February 7, 2019
1Highlights in Business Results(unit: JPY million)
Apr. - Dec. 2017
Results

Net sales

Apr. - Dec. 2018
Results

Year-overYear

Diff.

41,98344,251

2,267

5.4%

Operating profit

548

1,374

826

150.6%

Ordinary profit

713

1,419

706

99.0%

Profit attributable toowners of parent

497

980

482

96.9%

JPY 20.43

JPY 40.22------US Dollar

111.70111.14Euro

124.55130.97Singapore Dollar

81.60

81.80

Basic earnings per share※
Exchange Rate(averageduring period)(unit: JPY)

Overseas-Increased sales of Apheresis kit

Profit

Japan

Sales

-Increased sales of New Hemodialysis Machine “GC-X01”
and Dysphagia related products

Increased in sales (2nd straight year)
and increased in profit.

-The influence of increased sales and the decrease of
selling cost, resulted in profit increase※We have conducted a share consolidation of common stock of JMS Co., Ltd. pursuant to which two (2) shares were consolidated into one (1) share effective as of October 1, 2017.
Accordingly, the “Net income per share” has been calculated assuming that such share consolidation has been conducted at the beginning of the previous fiscal year.

2Summary by segment (geographical area)(unit: JPY million)Japan
30,691
28,233

31,946Singapore *■ Sales incl.
internal transaction■ Sales for third party－ Profit

Apr. - Dec.
2017

■ Sales incl.
internal transaction
15,098 ■ Sales for third party－ Profit

2,643
2,357

■ Sales incl.
internal transaction■ Sales for third party－ Profit

29,639
Sales
Increased
4.1%

393

14,338

China

518

ProfitIncreased
31.8%

Apr. - Dec.
2018

7,069

7,565
901

619
Apr. - Dec.
2017

Sales
Decreased
10.8%

Sales
Increased
5.3%
ProfitIncreased
45.5%

Apr. - Dec.
2018

1,008
25
Apr. - Dec.
2017

1,111
39

ProfitIncreased
53.5%

Apr. - Dec.
2018

[Sales][Sales]Increased sales of Apheresis kit for North
America market raised net sales.

[Sales]Decreased sales of Infusion Sets for Japan
market due to production transfer toPhilippines reduced net sales.

[Ordinary profit][Ordinary profit]
The influence of increase sales resulted inprofit increase.

[Ordinary profit]
The influence of decreased labor cost andexpense resulted in profit increase.

Increased sales of New Hemodialysis Machine“GC-X01” and Dysphagia related products
raised net sales.
The decrease of selling cost resulted in profit
increase.

*This segment includes Indonesia local subsidiary.

3

Summary by segment (geographical area)(unit: JPY million)

Philippines
1,257

Others *■ Sales incl.
internal transaction－ Profit■ Sales for third party－ Profit

5,672(483)Apr. - Dec.
2017

5,934

Sales
Increased
199.4%

419(354)

ProfitImproved by129
million yen

Apr. - Dec.
2018

[Sales]Increased sales of Infusion Sets for Japan
market raised net sales.
[Ordinary profit]
The influence of increased sales reduced loss.

～Product introduction～

Sales
Increased
4.6%

268

Apr. - Dec.
2017

355

ProfitIncreased
32.5%

Apr. - Dec.
2018

*This segment includes business activity of domestic
subsidiaries, Germany, United States and South Korea.

Hemodialysis Machines
Hemodialysis machine is a device for pulling
blood from a patient into an extracorporeal
circuit. The blood is purified by a dialyzer andreturned to the patient by the hemodialysis
machine.

4

Sales by Business Segment
Apr. – Dec. 2017

17,301

Apr. – Dec. 2018

Others 2.5%

Transfusion
17.6%

18,013

12,773

14,073

Cardiovascular
7.4%(unit: JPY million)

Apr. – Dec.
2018

Infusion & Nutrition
40.7%

Dialysis
31.8%

7,274
3,510

7,785

3,274
1,123

Infusion & Nutrition

Dialysis

CardiovascularTransfusion

1,104

Others5

Sales change by Region (Customer's Location)
Europe8.5%
North America
11.6%
Asia13.0%

Others2.0%

Apr. – Dec.
2018

(unit: JPY million)
Japan
64.9%

Sales composition

642
1,294

270

44,251(2)41,983Apr. - Dec. 201763

Increased
JPY 2,267 million

Japan

Asia

North AmericaEurope

OthersApr. - Dec. 20186

Selling, General and Admin. Expenses(unit: JPY million)
10,221

24.3%(unit: JPY million)

10,16123.0%

Apr. - Dec.
2018

Labor Cost

4,345

4,372

270.6%

Transport

1,210

1,244

33

2.8%

R&D

1,072

1,147

74

7.0%

258

248(9)(3.8%)

3,334

3,148(185)(5.6%)

10,22110,161(59)(0.6%)

Depreciation
Others
Total

Apr. - Dec.
2017

Apr. - Dec.
2018

Year-overYear

Apr. - Dec.
2017

Diff.

[R & D]
Clinical trial expense for the development of a new product continued.
[Others]
Sales commission decreased.

7Ordinary profit : Compared with the previous year
(unit: JPY million)

Minus factor
Apr. - Dec. 2017

Plus factor

713
Increase ofGross Profit

605
66
Increased
JPY 706 million

Decrease of
Non-operating profit

（94）
128

Apr. - Dec. 2018

Decrease of SGA

Impact ofExchange rate

1,419
The underlined figures exclude impact of exchange rate.
8Forecast for FYE Mar. 2019
(unit: JPY million)FYE Mar. 2019 Forecast

FYE Mar. 2018
ResultPrevious Forecast

56,52058,00058,000

2.6%

Operating profit

573

1,000

1,500

161.4%

Ordinary profit

820

1,200

1,500

82.8%

Profit attributable toowners of parent

631

800

1,10074.3%

JPY 25.91

JPY 32.83

JPY 45.13---US Dollar

110.85105111

Euro

126.67130130Singapore Dollar

81.74

82

82

Net sales

Basic earnings per share
Exchange Rate(average duringperiod)(unit: JPY)

Year-overYear

New Forecast

Consolidated business forecast for the fiscal year ending March 31, 2019 has been revised, due to the before-mentioned business results.

9Topics※Announcement date-Announcement of finished the production of Ono Plant
Sep. 26, 2018

-Announcement of disposition of treasury shares as the stock compensation plan with transferrestrictions
Jul. 18, 2018

-Announcement of introduction of the stock compensation plan with transfer restrictions
May. 18, 2018

-Launching new product “TWIN SHIELD” , Catheter connection system
Apr. 18, 2018

「TWIN SHIELD」

10

The Bridge to Good Health Care

The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.

11